重度哮喘生物治疗的长期疗效评估及治疗调整考量
Evaluation of Long-Term Response to Biological Therapy in Severe Asthma and Considerations for Treatment Adjustment.
作者信息
Giordani Jordan, Pini Alessandro, Pini Laura
机构信息
Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.
Department of Emergency, Anaesthesiological and Resuscitation Sciences, University Cattolica Sacro Cuore, 00168 Rome, Italy.
出版信息
J Clin Med. 2025 Apr 11;14(8):2623. doi: 10.3390/jcm14082623.
Abstract
Assessing long-term responses to biological therapies for severe asthma is critical for optimizing patient management and improving clinical outcomes [...].
摘要
评估重度哮喘生物疗法的长期反应对于优化患者管理和改善临床结局至关重要[……]。
相似文献
1
Evaluation of Long-Term Response to Biological Therapy in Severe Asthma and Considerations for Treatment Adjustment.重度哮喘生物治疗的长期疗效评估及治疗调整考量
J Clin Med. 2025 Apr 11;14(8):2623. doi: 10.3390/jcm14082623.
2
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].[支气管哮喘防治指南（2024年版）]
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.
3
Efficacy Assessment of Biological Treatments in Severe Asthma.重症哮喘生物治疗的疗效评估
J Clin Med. 2025 Jan 7;14(2):321. doi: 10.3390/jcm14020321.
4
Considerations in the long-term management of asthma in ambulatory patients.门诊患者哮喘长期管理的考量因素
Am J Health Syst Pharm. 2006 May 15;63(10 Suppl 3):S14-21. doi: 10.2146/ajhp060128.
5
Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies.接受生物疗法治疗的重度哮喘患者的临床反应与缓解情况。
Chest. 2024 Feb;165(2):253-266. doi: 10.1016/j.chest.2023.10.046. Epub 2023 Nov 3.
6
Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.在重度哮喘患者的真实队列中，使用不同标准比较奥马珠单抗和抗IL-5/IL-5R的长期反应与缓解情况。
Arch Bronconeumol. 2024 Jan;60(1):23-32. doi: 10.1016/j.arbres.2023.11.011. Epub 2023 Nov 22.
7
Optimizing care for children with difficult-to-treat and severe asthma through specialist paediatric asthma centres: expert practical experience and advice.通过专科儿科哮喘中心优化难治性和严重哮喘儿童的护理：专家实践经验和建议。
BMC Pediatr. 2024 Mar 27;24(1):218. doi: 10.1186/s12887-024-04707-0.
8
Cohort multiple randomized controlled trial in pediatric asthma to assess the long- and short-term effects of eHealth interventions: protocol of the CIRCUS study.一项评估电子健康干预措施对儿童哮喘长期和短期影响的队列多重随机对照试验：CIRCUS研究方案
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251323192. doi: 10.1177/17534666251323192. Epub 2025 Mar 12.
9
Prediction of response to biological treatment with monoclonal antibodies in severe asthma.严重哮喘中生物治疗单克隆抗体应答的预测。
Biochem Pharmacol. 2020 Sep;179:113978. doi: 10.1016/j.bcp.2020.113978. Epub 2020 Apr 17.
10
Biological therapy management from the initial selection of biologics to switching between biologics in severe asthma.严重哮喘中从生物制剂初始选择到生物制剂间转换的生物治疗管理。
Tuberk Toraks. 2023 Mar;71(1):75-93. doi: 10.5578/tt.20239910.
本文引用的文献
1
The effect of benralizumab on inflammation in severe asthma: a real-life analysis.倍那珠单抗对重度哮喘炎症的影响：一项真实世界分析。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241304685. doi: 10.1177/17534666241304685.
2
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.使用贝那利珠单抗治疗哮喘和慢性阻塞性肺疾病的嗜酸性粒细胞性加重（ABRA）：一项双盲、双模拟、活性安慰剂对照的随机试验。
Lancet Respir Med. 2025 Jan;13(1):59-68. doi: 10.1016/S2213-2600(24)00299-6. Epub 2024 Nov 29.
3
Biologics and airway remodeling in asthma: early, late, and potential preventive effects.生物制剂与哮喘气道重塑：早期、晚期及潜在预防作用
Allergy. 2025 Feb;80(2):408-422. doi: 10.1111/all.16382. Epub 2024 Nov 9.
4
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.每半年一次使用德佩莫单抗治疗嗜酸性粒细胞型重度哮喘。
N Engl J Med. 2024 Dec 19;391(24):2337-2349. doi: 10.1056/NEJMoa2406673. Epub 2024 Sep 9.
5
SANI clinical remission definition: a useful tool in severe asthma management.SANI 临床缓解定义：重症哮喘管理的有用工具。
J Asthma. 2024 Dec;61(12):1593-1600. doi: 10.1080/02770903.2024.2376919. Epub 2024 Jul 23.
6
Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study.度普利尤单抗治疗中重度哮喘患者气道高分泌和气道壁增厚的疗效：一项前瞻性观察研究。
Allergol Int. 2024 Jul;73(3):406-415. doi: 10.1016/j.alit.2024.02.002. Epub 2024 Mar 12.
7
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study.奥马珠单抗治疗重度哮喘：对口服皮质类固醇暴露和重塑的影响。一项随机开放标签平行研究。
Drugs. 2023 Aug;83(12):1111-1123. doi: 10.1007/s40265-023-01905-5. Epub 2023 Jul 12.
8
Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy.重度哮喘的生物制剂：真实世界证据、换药有效性及疗效预测因素
Allergol Int. 2023 Jan;72(1):11-23. doi: 10.1016/j.alit.2022.11.008. Epub 2022 Dec 19.
9
Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study.重度哮喘的真实世界生物制剂使用及转换模式：来自国际重度哮喘注册研究和美国CHRONICLE研究的数据
J Asthma Allergy. 2022 Jan 13;15:63-78. doi: 10.2147/JAA.S328653. eCollection 2022.
10
Biologic Therapies for Severe Asthma.重度哮喘的生物疗法
N Engl J Med. 2022 Jan 13;386(2):157-171. doi: 10.1056/NEJMra2032506.
Zotero 插件